BIOGEN INC. - COMMON STOCK

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

17 апр 2024 09:50:10 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

16 апр 2024 09:45:06 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

15 апр 2024 09:45:35 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

12 апр 2024 12:00:50 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

10 апр 2024 09:45:08 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

05 апр 2024 09:45:10 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

04 апр 2024 09:53:33 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

03 апр 2024 09:55:31 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

02 апр 2024 09:45:41 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 апр 2024 10:34:07 Источник NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

26 мар 2024 09:50:02 Источник NetDania Notify

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

06 мар 2024 07:30:51 Источник Nasdaq GlobeNewswire

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

04 мар 2024 16:15:57 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 мар 2024 09:47:17 Источник NetDania Notify

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

23 фев 2024 07:00:26 Источник Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

20 фев 2024 09:45:15 Источник NetDania Notify

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

12 фев 2024 16:06:00 Источник Nasdaq GlobeNewswire

Biogen to Realign Resources for Alzheimer's Disease Franchise

31 янв 2024 07:30:00 Источник Nasdaq GlobeNewswire

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

19 дек 2023 07:30:21 Источник Nasdaq GlobeNewswire

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

15 дек 2023 09:05:25 Источник Nasdaq GlobeNewswire